Drugs like Trikafta, first approved in 2019, have changed cystic fibrosis from a death sentence to a manageable chronic condition for the vast majority of patients. But the drug is only approved for c...

Michelle Lee's startup Medra raises $11M to build AI-powered lab robots, attracting Genentech and others as customers. The Stanford PhD aims to automate 70% of lab instruments with flexible robotic sy...

Biopharma’s relationship with AI is reaching a tipping point. While Big Pharma doubles down on AI to streamline development, a wave of startups is betting the tech can overhaul R&D from the ground up....

Eli Lilly is offering an unusual deal to any biotech: contribute some data, and in exchange, get access to many of Lilly's own AI models. The initiative, called TuneLab, debuted ...

Leal Therapeutics raises Series A funding led by SV Health Investors for neurology drugs LTX-001 and LTX-002. CEO Asa Abeliovich plans clinical trials through 2026.

OpenAI and Retro Biosciences report AI-made proteins showed 50x better cell reprogramming using modified Yamanaka factors, with potential therapeutic applications

Formation Bio licenses first-in-class anti-CD226 antibody from IMIDomics for IBD treatment, marking first drug acquisition since $372M Series D raise in 2023.

Revolution Medicines has become one of the industry's most valuable pre-commercial companies thanks to its pipeline of clinical-stage cancer drugs. CEO Mark Goldsmith is pressing ahead on ...

Biopharma CEO median pay hit $4.73M in 2024, up 40%. 20 CEOs made over $20M, including Pfizer's Bourla, Vertex's Kewalramani, Amgen's Bradway & Royalty Pharma's Legorreta.

The company felt 'fairly blindsided' upon reading the report that FDA Commissioner Marty Makary had briefly yet unsuccessfully tried to intervene in the review of its newly-approved HAE drug.

FDA approves KalVista Pharmaceuticals' sebetralstat for hereditary angioedema after controversy involving FDA Commissioner Makary's attempted intervention in review process

US investors debate response to China's rise in drug development, with some seeing a national security threat while others embrace collaboration. FDA and policymakers consider reforms to maintain comp...

FDA Commissioner Marty Makary’s unsuccessful attempt to intervene in an ongoing drug review, as described by multiple agency sources, raises further concerns about the regulator under its new leadersh...

FDA Commissioner Marty Makary reportedly attempted to reject KalVista Pharmaceuticals' drug application, sources said. An HHS spokesperson calls the claim 'totally false.'

Basecamp Research's global expeditions built BaseData, containing 9.8B protein sequences - 10x larger than public datasets - to advance AI biology models with Nvidia

Startup Bexorg, led by Zvonimir Vrselja, keeps human brains alive to test drugs. Their BrainEx system sustains brain cells for 24 hours to improve drug development and reduce animal testing.

The Salt Lake City-based biotech disclosed the job cuts in an SEC filing on Tuesday morning. More than 150 employees are likely being let go.

MIT scientists unveil Boltz-2, a new AI model predicting drug binding affinities. Led by Gabriele Corso, Saro Passaro & Jeremy Wohlwend, it outperforms previous AI methods in drug discovery.

The biotech fund — officially called Amplify Bio Fund I — plans to make about 20 investments exclusively in pre-seed, seed and Series A rounds.

Richard Saynor discusses his 35-year career in generics, Sandoz's 80% stock rise since the Novartis spinoff, and views on drug pricing and FDA changes.

ProteinQure raises $11M Series A led by Heron Rock to advance PQ203, a peptide-drug conjugate for triple-negative breast cancer, into clinical trials by Q3, pivoting from quantum to AI.

Beam Therapeutics CEO John Evans warns against AI hype in drug development, drawing parallels to past CRISPR expectations, responding to DeepMind CEO's disease cure claims.

Biotech companies face financial strain from expensive long-term leases signed during pandemic boom, with Ginkgo Bioworks, Prime Medicine & others struggling with high lease obligations amid market do...

Datavant acquires Aetion in health data merger. Deal doubles life sciences team to 400. CEO Kyle Armbrester says company has $1B+ revenue. Terms undisclosed. More M&A expected.

Recursion has cut five drug programs as CEO Chris Gibson focuses on 'winners' in its pipeline.

Iambic Therapeutics enhances AI model Enchant v2 with 10x more training data, improving drug property predictions.

Stately Bio has raised a $12 million seed round led by AIX Ventures to advance machine learning techniques that recognize signals from simple images of living cells.

An interview with Patrick Hsu, 31, Harvard PhD grad and CRISPR pioneer, who co-founded Arc Institute and helped develop Evo 2, a biology-focused AI model.

Live stream podcast tomorrow at 12pm ET with Drew Armstrong, Max Bayer & Anna Brown discussing pharma industry's response to Trump administration tariffs, including lobbying & manufacturing changes.

Brandon White launches Axiom, a biotech using AI to predict drug toxicity, with $15M seed funding. Former Uber employee aims to replace animal testing with simulation models.

Nicholas Johnston launches Alis Biosciences, targeting struggling biotechs with $30B in trapped capital and aiming to return cash to shareholders.

Several of the world’s largest pharma companies — Merck, Bristol Myers Squibb, Sanofi and Roche — were eager to position themselves as fully prepared for whatever may come next.

BigHat Biosciences has added another pharma partner and more cash to its balance sheet as the antibody specialist prepares to enter the clinic next year. The Bay Area startup will ...

The London biotech Charm Therapeutics is looking for a new top executive to replace founding CEO Laksh Aithani, Endpoints News has learned.

It’s a biotech environment without many good choices. Even before President Donald Trump’s tariff announcement pushed stock indices toward a bear market, biotech M&A has been virtually nonexistent, wi...

Former Pfizer CSO Mikael Dolsten joins Formation Bio to lead drug-picking committee and help train AI systems, as startup aims to create AI version of veteran drug hunter's expertise.

Isomorphic Labs CEO Demis Hassabis discusses $600M funding round, plans for a US office, and expanding into biologics/antibodies.

Mass firings and forced resignations swept through the FDA on Tuesday, as part of thousands of planned job cuts at federal health agencies being implemented by the Trump administration.

Isomorphic Labs, one of the leading AI-driven drug discovery companies within Alphabet, has reeled in $600 million in external financing as it nears the clinic.

Alcon acquires majority stake in Aurion, replaces CEO Greg Kunst with Arnaud Lacoste amid legal battle. Plans Phase 3 trial of AURN001 eye therapy this fall.

Duke professor Pranam Chatterjee discusses AI in biology, advocating for sequence-based over structure-based protein models, and warns of a

VantAI unveils Neo-1, an AI model that simultaneously predicts biomolecule structures and generates new molecular glues, claiming advancement beyond AlphaFold 3's capabilities.

Something changed for Bill Anderson when he turned 50. He was ascending the ranks of Roche’s Genentech, but the Texas native felt like he was stuck in the same loop ...

Something changed for Bill Anderson when he turned 50. He was ascending the ranks of Roche’s Genentech, but the Texas native felt like he was stuck in the same loop ...

One of biotech's best-funded startups has just raised a huge new round to take its lead drug into final-stage testing. On Wednesday, Eikon Therapeutics announced a $351 million Series D ...

Pharma executives at PhRMA Forum avoid discussing controversial Trump administration health policies while praising him as

On a sunny September day in 2023, scientists at CRISPR Therapeutics invited me to peer through their microscopes. Through the lens were liver cells, part of the company’s work to gear up for a clinica...

Patrick Hsu and team unveil Evo 2, an AI model trained on nine trillion DNA base pairs from 128,000+ species, developed by Arc Institute and Nvidia researchers.

Over 500 pharma executives, lobbyists, consultants and other industry members gathered a couple miles from the White House on Tuesday, as top industry leaders took the stage and tried out some new mes...